PAMAfrica

Portfolio approach to developing the next-generation of malaria treatments for Africa

News

1

PAMAfrica and the evolution of good clinical trials

PAMAfrica and the evolution of good clinical trials

PAMAfrica's Dr Bérenger Kaboré and Dr Helen Demarest discuss the consortium's approach to conducting clinical trials in the context of the recently published WHO Guidance for best practices for clinical trials.

Communications training for malaria researchers

Communications training for malaria researchers

This summer, the PAMAfrica consortium organized and facilitated a series of communications workshops for a group of PAMAfrica and SINDOFO scholarship students to help enhance their presentation skills and expand their social media presence.

Delivering better healthcare outcomes through PAMAfrica’s CALINA study

Delivering better healthcare outcomes through PAMAfrica’s CALINA study

This April, Novartis and Medicines for Malaria Venture (MMV) announced positive data from the Phase 2/3 CALINA study conducted through PAMAfrica’s Work Package 2.

PAMAfrica-SINDOFO capacity building symposium at MIM 2024

Recap: PAMAfrica-SINDOFO capacity building symposium at MIM 2024

Following a successful joint symposium at the 11th EDCTP Forum, the PAMAfrica and SINDOFO consortia hosted a capacity building symposium at this year’s MIM Society Conference in Kigali, Rwanda.

PAMAfrica-SINDOFO capacity building symposium at the MIM Society Conference

SwissCore: PAMAfrica’s role in the global fight against malaria

SwissCore, the Swiss information and liaison office for European policies and programs in research, innovation and education located in Brussels, recently published an article about PAMAfrica’s role in the global fight against malaria, and how MMV is developing best practices when it comes to engaging in global, multi-country research partnerships.

PAMAfrica marks World Malaria Day

PAMAfrica marks World Malaria Day

On World Malaria Day, PAMAfrica partners reflect on how the consortium is contributing to the ambition of accelerating the fight against malaria for a more equitable world.

Medicines for Malaria Venture and Novartis announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria

Medicines for Malaria Venture and Novartis announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria

MMV and Novartis announce positive data from their phase II/III CALINA study, demonstrating that a novel formulation of Coartem® developed for babies weighing less than 5kg with malaria has the required pharmacokinetic profile and therefore efficacy and safety.

ISGlobal symposium at MIM 2024

A symposium to create awareness of malaria prevalence in young infants and advocate for appropriate treatment.

PAMAfrica student poster presentations at the 8th MIM Society Conference

PAMAfrica PhD student poster presentations at the 8th MIM Society Conference

PAMAfrica PhD students Francis Bouhissou, Nouhoun Barry and Victor Asua will be sharing their research via poster presentations at this year's MIM Society Conference.

PAMAfrica/SINDOFO capacity building symposium at MIM 2024

The PAMAfrica and SINDOFO consortia are hosting joint capacity building symposium at the 8th MIM Society Conference in Kigali, Rwanda.

Celebrating International Day of Women and Girls in Science 2024

Meet four scientists contributing to the malaria elimination agenda and the future of African research through their work.

The Guardian: Could new malaria drug give babies a better chance of survival?

The Guardian: Could new malaria drug give babies a better chance of survival?

Caroline Kimeu, the Guardian's east Africa global development correspondent, recently wrote an article on PAMAfrica's Work Package 3 trial.

Pages